Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 24;10(1):94.
doi: 10.1186/s13045-017-0453-8.

Immunotherapy in hematologic malignancies: past, present, and future

Annie Im  1 , Steven Z Pavletic  2
Affiliations
Review

Immunotherapy in hematologic malignancies: past, present, and future

Annie Im et al. J Hematol Oncol. .

Abstract

The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatment landscape for a variety of solid malignancies. Prior to its designation as the Science Breakthrough of the Year in 2013, cancer immunotherapy was active in the treatment of hematologic malignancies. This review provides a broad overview of the past, present, and potential future of immunotherapy in hematologic malignancies.

Keywords: Hematologic malignancies; Immunotherapy; Stem cell transplantation.

PubMed Disclaimer

References

    1. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432–1433. doi: 10.1126/science.342.6165.1432. - DOI - PubMed
    1. Mukherjee S. The emperor of all maladies. New York: Scribner; 2010.
    1. Pasquini, M.C., and Zhu, X. Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR summary slides. 2015. http://www.cibmtr.org. Accessed 2017.
    1. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562. - PubMed
    1. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–1073. doi: 10.1056/NEJM197905103001902. - DOI - PubMed

MeSH terms